DE69203443T2 - Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. - Google Patents
Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.Info
- Publication number
- DE69203443T2 DE69203443T2 DE69203443T DE69203443T DE69203443T2 DE 69203443 T2 DE69203443 T2 DE 69203443T2 DE 69203443 T DE69203443 T DE 69203443T DE 69203443 T DE69203443 T DE 69203443T DE 69203443 T2 DE69203443 T2 DE 69203443T2
- Authority
- DE
- Germany
- Prior art keywords
- interleukin
- tils
- cancer
- adoptive immunotherapy
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000003814 Interleukin-10 Human genes 0.000 title abstract 5
- 108090000174 Interleukin-10 Proteins 0.000 title abstract 5
- 229940076144 interleukin-10 Drugs 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract 5
- 102000000588 Interleukin-2 Human genes 0.000 abstract 4
- 108010002350 Interleukin-2 Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64134291A | 1991-01-16 | 1991-01-16 | |
PCT/US1992/000067 WO1992012726A1 (en) | 1991-01-16 | 1992-01-15 | Use of interleukin-10 in adoptive immunotherapy of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69203443D1 DE69203443D1 (de) | 1995-08-17 |
DE69203443T2 true DE69203443T2 (de) | 1995-12-07 |
Family
ID=24571960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69203443T Expired - Fee Related DE69203443T2 (de) | 1991-01-16 | 1992-01-15 | Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. |
Country Status (17)
Country | Link |
---|---|
US (1) | US5776451A (de) |
EP (2) | EP0567586B1 (de) |
JP (1) | JPH06505250A (de) |
CN (1) | CN1063308A (de) |
AT (1) | ATE124866T1 (de) |
AU (1) | AU1273992A (de) |
DE (1) | DE69203443T2 (de) |
DK (1) | DK0567586T3 (de) |
ES (1) | ES2074879T3 (de) |
GR (1) | GR3017597T3 (de) |
IE (1) | IE68836B1 (de) |
IL (1) | IL100667A0 (de) |
MX (1) | MX9200161A (de) |
MY (1) | MY108267A (de) |
NZ (1) | NZ241321A (de) |
WO (1) | WO1992012726A1 (de) |
ZA (1) | ZA92304B (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW381026B (en) * | 1993-01-13 | 2000-02-01 | Schering Corp | Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells |
AU707019B2 (en) * | 1994-01-20 | 1999-07-01 | Schering Corporation | Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity |
US5770190A (en) * | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
WO1997031532A1 (en) * | 1996-02-28 | 1997-09-04 | University Of Medicine & Dentistry Of New Jersey | Antisense interleukin 10 and methods of use |
JP2001500369A (ja) | 1996-08-30 | 2001-01-16 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | インターロイキン―19 |
AU6517900A (en) * | 1999-08-03 | 2001-02-19 | Smith & Nephew, Inc. | Controlled release implantable devices |
EP1349873B1 (de) | 2000-09-14 | 2009-04-01 | Beth Israel Deaconess Medical Center, Inc. | Modulierung von il-2 und il-15 vermittelten t zellantworten |
EP1324779B1 (de) | 2000-09-29 | 2011-07-20 | Schering Corporation | Pegyliertes interleukin 10 |
JP2006522022A (ja) | 2003-02-14 | 2006-09-28 | ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ | プロテアソーム干渉に関連する避妊法および組成物 |
US7294262B2 (en) * | 2003-08-27 | 2007-11-13 | Sta-Rite Industries, Llc | Modular fluid treatment apparatus |
CA2664304C (en) | 2006-09-28 | 2017-08-22 | Schering Corporation | Use of pegylated il-10 to treat cancer |
US20080089875A1 (en) * | 2006-10-13 | 2008-04-17 | Zheng Cui | Methods and compositions for the treatment of cancer |
EP2374813A1 (de) | 2008-12-03 | 2011-10-12 | Proyecto de Biomedicina Cima, S.L. | Verwendung von phenollöslichen modulinen zur entwicklung von impfstoffen |
PL2379115T3 (pl) | 2008-12-17 | 2018-03-30 | Merck Sharp & Dohme Corp. | Wytwarzanie i zastosowania mono- i di-peg il-10 |
CA2750922A1 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-key hybrid peptides that modulate the immune response to influenza |
SG10201407936XA (en) * | 2009-11-30 | 2015-01-29 | Biotest Ag | Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) |
WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
EP2505640A1 (de) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten |
EP2986306A4 (de) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden |
US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
JP6509867B2 (ja) | 2013-08-30 | 2019-05-08 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためにインターロイキン−10を使用する方法 |
KR20160083884A (ko) | 2013-11-01 | 2016-07-12 | 스페리움 바이오메드 에스.엘. | 치료제 및 미용제의 경피 전달을 위한 봉입체 |
ES2862139T3 (es) | 2013-11-11 | 2021-10-07 | Armo Biosciences Inc | Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos |
US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
JP6728061B2 (ja) | 2014-05-05 | 2020-07-22 | リセラ・コーポレイションLycera Corporation | RORγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療 |
JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
JP2017536098A (ja) | 2014-10-14 | 2017-12-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−15組成物及びその使用 |
KR20170084033A (ko) | 2014-10-22 | 2017-07-19 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법 |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
CN107847583A (zh) | 2015-05-28 | 2018-03-27 | 阿尔莫生物科技股份有限公司 | 用于治疗癌症的聚乙二醇化白细胞介素‑10 |
MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
AU2016312510A1 (en) | 2015-08-25 | 2018-03-08 | Armo Biosciences, Inc. | Methods of using Interleukin-10 for treating diseases and disorders |
WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
US20200368293A1 (en) * | 2018-01-18 | 2020-11-26 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
TW202120521A (zh) | 2019-08-16 | 2021-06-01 | 美商應用分子運輸公司 | 組合物、配方及介白素生產及純化 |
CN110669139A (zh) * | 2019-09-18 | 2020-01-10 | 沣潮医药科技(上海)有限公司 | 二聚体免疫粘附素、药物组合物和用途 |
CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
CN114805538B (zh) * | 2022-05-20 | 2023-06-09 | 广州智瓴生物医药有限公司 | 一种增强til功效的培养方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
JPH0751496B2 (ja) * | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
WO1990004633A1 (en) * | 1988-10-21 | 1990-05-03 | Brigham And Women's Hospital | ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR |
DE69012105T2 (de) * | 1989-02-21 | 1994-12-22 | Terumo Corp | Proliferation von cd4-lymfocyten. |
IL94878A (en) * | 1989-06-28 | 2003-01-12 | Schering Corp | Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same |
-
1992
- 1992-01-15 ES ES92905179T patent/ES2074879T3/es not_active Expired - Lifetime
- 1992-01-15 AU AU12739/92A patent/AU1273992A/en not_active Abandoned
- 1992-01-15 AT AT92905179T patent/ATE124866T1/de not_active IP Right Cessation
- 1992-01-15 MX MX9200161A patent/MX9200161A/es unknown
- 1992-01-15 DK DK92905179.5T patent/DK0567586T3/da active
- 1992-01-15 WO PCT/US1992/000067 patent/WO1992012726A1/en active IP Right Grant
- 1992-01-15 JP JP4505288A patent/JPH06505250A/ja active Pending
- 1992-01-15 EP EP92905179A patent/EP0567586B1/de not_active Expired - Lifetime
- 1992-01-15 EP EP92300331A patent/EP0495639A1/de active Pending
- 1992-01-15 IE IE920113A patent/IE68836B1/en not_active IP Right Cessation
- 1992-01-15 MY MYPI92000065A patent/MY108267A/en unknown
- 1992-01-15 IL IL100667A patent/IL100667A0/xx unknown
- 1992-01-15 DE DE69203443T patent/DE69203443T2/de not_active Expired - Fee Related
- 1992-01-15 ZA ZA92304A patent/ZA92304B/xx unknown
- 1992-01-16 CN CN92100319A patent/CN1063308A/zh active Pending
- 1992-01-16 NZ NZ241321A patent/NZ241321A/en unknown
-
1994
- 1994-07-05 US US08/270,805 patent/US5776451A/en not_active Expired - Fee Related
-
1995
- 1995-10-02 GR GR950402710T patent/GR3017597T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
GR3017597T3 (en) | 1996-01-31 |
US5776451A (en) | 1998-07-07 |
IE68836B1 (en) | 1996-07-10 |
EP0567586A1 (de) | 1993-11-03 |
MY108267A (en) | 1996-09-30 |
ATE124866T1 (de) | 1995-07-15 |
WO1992012726A1 (en) | 1992-08-06 |
EP0567586B1 (de) | 1995-07-12 |
MX9200161A (es) | 1992-07-01 |
DK0567586T3 (da) | 1995-12-04 |
DE69203443D1 (de) | 1995-08-17 |
IL100667A0 (en) | 1992-09-06 |
ES2074879T3 (es) | 1995-09-16 |
JPH06505250A (ja) | 1994-06-16 |
ZA92304B (en) | 1992-09-30 |
AU1273992A (en) | 1992-08-27 |
EP0495639A1 (de) | 1992-07-22 |
NZ241321A (en) | 1997-06-24 |
CN1063308A (zh) | 1992-08-05 |
IE920113A1 (en) | 1992-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE124866T1 (de) | Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. | |
Niederwieser et al. | IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. | |
Rook et al. | The immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sézary T cells | |
ATE20073T1 (de) | Homogenes human-interleukin-2 und verfahren zu seiner herstellung. | |
EP0668781A4 (de) | Lymphokine gentherapie bei krebs. | |
DE69032086D1 (de) | Zytotoxischer Lymphozyten-Reifefaktor | |
EP0211769A3 (en) | Adoptive immunotherapy as a treatment modality in humans | |
ZA967756B (en) | Adoptive immunitherapy using macrophages sensitized with heat shock protein-epitope complexes | |
DK226288A (da) | Fremgangsmaade til fremstilling af lak-celler in vitro | |
DK0789588T3 (da) | Metode til fremstilling af et medikament til behandling af sekundær immundefekt | |
DE3678736D1 (de) | Labdanderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel. | |
ATE167519T1 (de) | T-zellen-wachstumsfaktor | |
Flynn et al. | Production of interleukin-1 and interleukin-2 in allogeneic mixed lymphocyte cultures under copper, magnesium and zinc deficient conditions | |
EP0094317A3 (de) | Herstellung von Interleukin und dessen analogen immunregulierenden Faktoren | |
DE3683956D1 (de) | In einem serumfreien medium in suspension kultivierte humane monozyten. | |
YU4792A (sh) | Postupak gajenja tumornih infiltirajućih limfocita | |
Hansson | Growth and differentiation factors for B and T cells | |
JPS57115180A (en) | Preparation of human tyroid-stimulating hormone | |
GR3018004T3 (en) | Process to prepare metastasis-inhibitory factor. | |
Whiteside | The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2 | |
GB8817082D0 (en) | Method for production of lymphokine activated killer(lak)cells so produced & their use | |
GB8729410D0 (en) | Method for production of lymphokine activated killer(lak)cells & lak cells so produced |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |